… ProQR to Present at the Leerink Partners 4th Annual Rare … be accessible from the 'Investor Relations' section of ProQR's website ( www.proqr.com ) under 'Events and Presentations'. The …
… ProQR Completes Dosing of Cystic Fibrosis Patients in QR-010 … including sweat chloride, weight gain, change in CFQ-R Respiratory Symptom Score and FEV 1 , however, the study is … said Noreen R. Henig MD, Chief Medical Officer at ProQR. “We are grateful to the patients and the medical …
… ProQR Initiates Phase 1/2 Clinical Trial of QR-313 for … LEIDEN, the Netherlands, June 28, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to … Executive Vice President of Research and Development at ProQR. “Now that the study is initiated we expect to dose the …
… ProQRR&D day Highlights Progress on Pipeline and Introduces … RNA Technology Key program features and updates: ProQR to host an R&D day in New York today, June 15, from … the nasal potential difference (NPD) study for QR-010, ProQR’s lead molecule for CF that is studied in two clinical …
Divestment of sepofarsen and ultevursen completed – Théa to continue development of sepofarsen and ultevursen for patients with LCA10 and Usher syndrome
… ProQR Announces Amendment to Convertible Debt Financing … (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR) (“ProQR”), a company dedicated to changing lives through the … said Smital Shah, Chief Business and Financial Officer of ProQR. “If fully drawn down, this facility extends our cash …
LEIDEN, Netherlands & CAMBRIDGE, Mass., April 22, 2024 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies, today announced it will present new preclinical data for its proprietary Axiomer™ RNA editing